Histone deacetylase inhibitors as antidiabetic agents: Advances and opportunities

Area of Science:

• Endocrinology and Metabolism
• Molecular Biology
• Epigenetics

Background:

• Diabetes mellitus involves pancreatic beta-cell dysfunction, linked to genetic and epigenetic changes.
• Histone deacetylases (HDACs) are increasingly recognized for their significant pathophysiological role in both type 1 and type 2 diabetes.
• HDACs are implicated in key diabetes-related events such as redox imbalance, endoplasmic reticulum stress, oxidative stress, and inflammation, all contributing to beta-cell deterioration.

Purpose of the Study:

• To review the critical pathways regulating different classes of HDACs.
• To explore the signaling networks between HDACs and diabetes-related stress mediators.
• To summarize the efficacy of HDAC inhibitors in managing diabetes and its complications.

Main Methods:

• Literature review of experimental studies investigating HDACs in diabetes.
• Analysis of signaling pathways involving HDACs and stress mediators.
• Synthesis of evidence on the therapeutic potential of HDAC inhibitors.

Main Results:

• HDACs are involved in major pathogenic events contributing to beta-cell dysfunction in diabetes.
• Inhibition of HDACs emerges as a potential therapeutic avenue.
• Various small molecule HDAC inhibitors have been explored in experimental settings.

Conclusions:

• HDACs are critical regulators of beta-cell function and survival in diabetes.
• Targeting HDACs with specific inhibitors offers a promising strategy for diabetes treatment.
• Further research into HDAC inhibitors is warranted for managing diabetes and its associated conditions.